March 1, 2024
“…Shares of Hims & Hers closed up 31% to $13.43 as of Tuesday afternoon. They’re now up more than 50% for the year after climbing 39% in 2023… Revenue jumped 47% to $246.6 million, topping the $246 million expected by… Continue Reading…
February 20, 2024
“Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with blockbuster potential as the U.S. drugmaker looks beyond its older HIV drugs for growth. Shares of the Newark, California-based drug developer jumped 24.6%… Continue Reading…
Recent Comments